Deep vein thrombosis: New drugs and future therapeutic perspectives;Trombosis venosa profunda: Nuevos fármacos y futuras perspectivas terapéuticas

Revista Clinica Espanola

Volumn 206, Issue 6, 2006, Pages 281-283

  Garcia Vidal R ^a,b   Berga Fauria, C ^a   Paredero, V M ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b NONE   (Spain)

Author keywords

Anticoagulation; Deep vein thrombosis; Fondaparinux; New antithrombotic treatment; Ximelagatran

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 2A INHIBITOR; BLOOD CLOTTING INHIBITOR; FONDAPARINUX; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NEW DRUG; RAZAXABAN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG DISPOSITION; DRUG MARKETING; DRUG SUBSTITUTION; HUMAN; LUNG EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 33746301443     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13088589     Document Type: Article

References (10)

1. Dobesh PP, Karissa K. The future of anticoagulation. J Pharm Practice. 2004;5:370-84
2. Weitz JI, Hirsh J, Meyer M. The seventh ACCP conference on antithrombotic and thrombolytic therapy. New anticoagulant drugs. Chest. 2004;126:265S-86S.
3. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgey Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715-20.
4. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, PENTATHALON 2000 Study. Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359:1721-6.
5. Eriksson BI, Lassen MR. PENTasaccharide in Hip-FRA-ture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163:1337-42.
6. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-702.
7. Gustafsson D, Nystrom JE, Carlsson S, Bredberg U, Erihsson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171-81.
8. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002;360:1441-7.
9. Eriksson BI, Agnelli G, Cohen AT, et al. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism in total hip or total knee replacement: the EXPRESS study [abstract]. Blood. 2002;100:299.
10. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003;1:41-7.